The 31 most recent market catalysts affecting $UTHR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage of United Therapeutics with Buy Rating
HC Wainwright & Co. has initiated coverage on United Therapeutics Corporation (UTHR) with a 'Buy' rating and a price target of $660. This represents a significant implied upside of…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy Rating and Increases Price Target for United Therapeutics
TD Cowen maintained its 'Buy' rating on United Therapeutics and raised its price target to $700 from $675. This 3.7% increase in the price target implies a 15.0% upside from the co…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Raises Price Target on United Therapeutics to $725
RBC Capital Markets has raised its price target for United Therapeutics (UTHR) to $725, up from $697, and maintained an 'Outperform' rating. This positive revision comes after the …
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
United Therapeutics Announces Acquisition of Pfizer Royalty Interest in Ralinepag
United Therapeutics has made a strategic move to acquire Pfizer's royalty interest in ralinepag, an experimental therapy for pulmonary arterial hypertension, for $525 million. This…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Raises Price Target on United Therapeutics
Investment firm BTIG has raised its price target for United Therapeutics (UTHR) from $728 to $768, while reiterating a 'Buy' rating. This 5.5% increase in the target price signals …
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
United Therapeutics Announces New $2 Billion Share Repurchase Authorization
United Therapeutics authorized a new $2 billion share repurchase program, a significant capital allocation decision. This move typically indicates management's belief that the comp…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 85
United Therapeutics Reports Third Quarter 2026 Financial Results
United Therapeutics reported record revenue for the third quarter of 2026, attributing this performance to strong commercial momentum and execution across the organization. This po…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
United Therapeutics Announces $525 Million Royalty Buydown with Pfizer Subsidiary Arena Pharmaceuticals
United Therapeutics (UTHR) has made a strategic move to buy out all future royalty obligations for its drug ralinepag from Arena Pharmaceuticals, a Pfizer (PFE) subsidiary, for an …
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 55
United Therapeutics Receives FDA Clearance for Treprostinil-Iloprost Phase 1 Trial
United Therapeutics announced FDA clearance to initiate a Phase 1 clinical trial for a novel treprostinil-iloprost combination therapy for PAH. This is a positive development as it…
Oct 22, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Markets Adjusts United Therapeutics Price Target
RBC Capital Markets adjusted its price target for United Therapeutics (UTHR) from $708 to $697. This change, while a reduction, is relatively minor and is accompanied by the contin…
Oct 22, 2026
Corporate Catalyst
Bearish
Impact 75
United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says
United Therapeutics and Liquidia have reached a settlement regarding their respective pulmonary hypertension therapies. This development is significant because it resolves ongoing …
Oct 20, 2026
Corporate Catalyst
Neutral
Impact 65
United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas
United Therapeutics has opened its third DPF facility, named after xenotransplantation pioneers, in Houston. This new facility, along with another recently opened in Minnesota, is …
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725
Leerink Partners, a prominent investment bank, has updated its outlook on United Therapeutics (UTHR) by raising its price target from $685 to $725 while maintaining an 'Outperform'…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 75
The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
United Therapeutics received FDA clearance to begin its Phase 2 SUMMIT trial for treprostinil SMI in PH-COPD. This is a crucial development because PH-COPD is a serious condition w…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708
RBC Capital's analyst Lisa Walter maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised the price target from $677 to $708. This action signals continued bull…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566
Morgan Stanley analyst Terence Flynn maintained an 'Equal-Weight' rating on United Therapeutics (UTHR) but raised the price target from $515 to $566. This action signals a slightly…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 92
United Therapeutics shares are trading higher after the company confirmed a patent litigation legal judgement in its favor in a claim against Liquidia. Also, BTIG upgraded its rating on the stock from Neutral to Buy and announced a $728 price target.
This headline presents a major positive catalyst for United Therapeutics (UTHR). The favorable patent litigation judgment removes a significant overhang and protects a key revenue …
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 65
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
The filing details multiple analyst upgrades across various sectors, indicating a positive shift in sentiment for these specific companies. For United Therapeutics (UTHR), the upgr…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 85
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
United Therapeutics (UTHR) announced a significant federal court victory against Liquidia (LQDA) concerning patent infringement related to inhaled treprostinil for PH-ILD. The cour…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 85
Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing
United Therapeutics (UTHR) has secured a significant victory in a Delaware court, finding Liquidia (LQDA) infringed on two claims of its patent for inhaled treprostinil, specifical…
Sep 29, 2026
Market Technicals
Neutral
Impact 55
10 Health Care Stocks Whale Activity In Today’s Session
The filing highlights 'whale' options activity in several health care stocks, indicating large institutional or sophisticated investor movements. This matters because such activity…
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 75
United Therapeutics shares are trading lower after Goldman Sachs initiated coverage on the stock with a Sell rating and announced a $321 price target.
This headline represents a significant corporate catalyst for United Therapeutics. A 'Sell' rating from a prominent firm like Goldman Sachs, coupled with a specific price target be…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321
Goldman Sachs analyst Andrea Newkirk initiated coverage on United Therapeutics (UTHR) with a 'Sell' rating and a $321 price target. This is a significant event for UTHR as a 'Sell'…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
United Therapeutics shares are trading higher after the company announced it would use the remaining sum of approximately $478 million from its $2 billion stock buyback authorization.
The announcement of United Therapeutics utilizing the remaining $478 million from its stock buyback authorization is a significant corporate catalyst. Stock buybacks reduce the num…
Sep 3, 2026
Market Technicals
Bearish
Impact 55
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
The filing highlights United Therapeutics (UTHR), Collegium Pharmaceutical (COLL), and Akso Health Group (AHG) as oversold based on their RSI values falling below 30. This technica…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona
United Therapeutics announced it will present data from eight clinical studies at the ESC 2026 and ERS 2026 conferences. This includes late-breaking analyses from Phase 3 studies f…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 65
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
United Therapeutics announced the full enrollment of its TETON-PPF study, which is evaluating Tyvaso for progressive pulmonary fibrosis. This is a positive operational milestone, i…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677
RBC Capital's analyst Lisa Walter maintained an 'Outperform' rating on United Therapeutics (UTHR) but lowered the price target from $704 to $677. This action suggests that while th…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 75
United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M Estimate
This headline presents a nuanced picture for United Therapeutics (UTHR). The EPS beat is a positive sign, potentially driven by efficient operations or favorable product mix, which…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAH
United Therapeutics announced the publication of the full results of its ADVANCE OUTCOMES study for ralinepag in The Lancet. This is a significant event as it validates the positiv…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687
JP Morgan analyst Jessica Fye maintained an 'Overweight' rating on United Therapeutics (UTHR) and slightly raised the price target from $685 to $687. This action signals continued …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.